| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $668,812 | 15 | 100 |
| Yoshiyama Annie | SVP, Finance | 0 | $0 | 2 | $29,311 | $-29,311 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | 0 | $0 | 5 | $51,672 | $-51,672 |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 0 | $0 | 2 | $90,940 | $-90,940 |
| Douglas Earl Martin | SVP, General Counsel | 0 | $0 | 2 | $103,262 | $-103,262 |
| Roberts Zachary | EVP of R&D | 0 | $0 | 2 | $104,169 | $-104,169 |
| Chang David D | President and CEO | 0 | $0 | 2 | $289,459 | $-289,459 |
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The …
Over the last 12 months, insiders at Allogene Therapeutics, Inc. have bought $0 and sold $668,812 worth of Allogene Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Allogene Therapeutics, Inc. have bought $3.57M and sold $473,652 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,724,137 shares for transaction amount of $5M was made by Belldegrun Arie (director) on 2024‑05‑16.
| 2026-10-21 | Sale | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 36,342 0.0106% | $1.34 | $48,698 | -7.52% | |
| 2026-08-21 | Sale | Douglas Earl Martin | SVP, General Counsel | 29,697 0.0092% | $2.12 | $62,958 | -22.49% | |
| 2026-04-21 | Sale | Yoshiyama Annie | SVP, Finance | 9,586 0.0039% | $2.31 | $22,144 | -16.16% | |
| 2026-03-31 | Sale | Beneski Benjamin Machinas | SVP, Chief Technical Officer | 2,867 0.0012% | $2.50 | $7,168 | -18.85% | |
| 2026-03-16 | Sale | Chang David D | President and CEO | 47,763 0.0215% | $2.47 | $117,975 | -18.03% | |
| 2026-03-16 | Sale | Beneski Benjamin Machinas | SVP, Chief Technical Officer | 4,835 0.0022% | $2.47 | $11,942 | -18.03% | |
| 2026-03-02 | Sale | Beneski Benjamin Machinas | SVP, Chief Technical Officer | 7,132 0.003% | $2.60 | $18,543 | -23.77% | |
| 2026-02-02 | Sale | Chang David D | President and CEO | 95,269 0.0408% | $1.80 | $171,484 | +8.29% | |
| 2026-02-02 | Sale | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 24,001 0.0101% | $1.76 | $42,242 | +8.29% | |
| 2026-02-02 | Sale | Roberts Zachary | EVP of R&D | 35,700 0.015% | $1.77 | $63,189 | +8.29% | |
| 2026-02-02 | Sale | Douglas Earl Martin | SVP, General Counsel | 22,900 0.0096% | $1.76 | $40,304 | +8.29% | |
| 2026-02-02 | Sale | Beneski Benjamin Machinas | SVP, Chief Technical Officer | 7,549 0.0031% | $1.73 | $13,060 | +8.29% | |
| 2026-02-02 | Sale | Yoshiyama Annie | SVP, Finance | 4,167 0.0017% | $1.72 | $7,167 | +8.29% | |
| 2026-01-21 | Sale | Roberts Zachary | EVP of R&D | 26,269 0.0114% | $1.56 | $40,980 | +25.00% | |
| 2025-11-17 | Sale | Beneski Benjamin Machinas | SVP, Chief Technical Officer | 786 0.0003% | $1.22 | $959 | +54.47% | |
| 2025-10-21 | Sale | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 36,744 0.0165% | $1.26 | $46,169 | +48.41% | |
| 2025-06-10 | Sale | MESSEMER DEBORAH M. | director | 36,885 0.0164% | $1.42 | $52,377 | -2.74% | |
| 2025-04-21 | Sale | Yoshiyama Annie | SVP, Finance | 9,601 0.0044% | $1.41 | $13,537 | -4.93% | |
| 2025-03-14 | Sale | Chang David D | President and CEO | 46,668 0.0225% | $1.96 | $91,469 | -30.67% | |
| 2025-03-14 | Sale | Beneski Benjamin Machinas | SVP, Chief Technical Officer | 5,488 0.0027% | $1.98 | $10,839 | -30.67% |
| Chang David D | President and CEO | 5150599 1.4908% | $5.77M | 1 | 7 | +2.3% |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 1045877 0.3027% | $1.17M | 1 | 4 | <0.0001% |
| PFIZER INC | 10 percent owner | 22032040 6.377% | $24.68M | 1 | 0 | +2.3% |
| TPG Group Holdings (SBS) Advisors, Inc. | 10 percent owner | 18716306 5.4173% | $20.96M | 1 | 17 | +2.3% |
| Belldegrun Arie | director | 1724137 0.499% | $1.93M | 4 | 0 | <0.0001% |
| Humer Franz B | director | 307507 0.089% | $344,407.84 | 1 | 2 | +2.3% |
| Kazam Joshua A | director | 258885 0.0749% | $289,951.20 | 1 | 0 | <0.0001% |
| WITTE OWEN N. | 218271 0.0632% | $244,463.52 | 1 | 5 | +2.3% |
$3,887,391 | 114 | 13.01% | $433.37M | |
$31,123,523 | 108 | 6.46% | $387.86M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$22,020,194 | 25 | 38.25% | $405.58M | |
$2,471,510 | 19 | 17.33% | $334.18M |
| Increased Positions | 86 | +48.86% | 17M | +12.2% |
| Decreased Positions | 65 | -36.93% | 14M | -9.79% |
| New Positions | 30 | New | 6M | New |
| Sold Out Positions | 21 | Sold Out | 1M | Sold Out |
| Total Postitions | 197 | +11.93% | 143M | +2.42% |
| Tpg Gp A, Llc | $25,267.00 | 8.32% | 18.72M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $23,645.00 | 7.78% | 17.51M | -382,726 | -2.14% | 2025-09-30 |
| Citadel Advisors Llc | $18,862.00 | 6.21% | 13.97M | +4M | +36.27% | 2025-09-30 |
| Vanguard Group Inc | $12,178.00 | 4.01% | 9.02M | +761,642 | +9.22% | 2025-09-30 |
| Primecap Management Co/Ca/ | $9,557.00 | 3.15% | 7.08M | +1M | +23.78% | 2025-09-30 |
| Woodline Partners Lp | $5,887.00 | 1.94% | 4.36M | 0 | 0% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $5,223.00 | 1.72% | 3.87M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $5,176.00 | 1.7% | 3.83M | +39,058 | +1.03% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $4,965.00 | 1.63% | 3.68M | -353,398 | -8.77% | 2025-09-30 |
| Ubs Group Ag | $4,821.00 | 1.59% | 3.57M | +2M | +75.15% | 2025-09-30 |